GET A QUOTE

Chlamydia Pneumoniae IgA ELISA Kit

  • Created on the 12 July, 2017.

BACKGROUND

Chlamydia pneumoniae is a gram negative bacterium which is a major cause of pneumonia. It was first identified in causing acute lower respiratory tract infections for example bronchitis and pneumonia in both children and adults. C. pneumoniae has the ability to infect a large number of different human cells which can include macrophages, lymphocytes, monocytes, endothelial, epithelial and smooth muscle cells. Many researcher have described Chlamydiae has energy parasites that are dependent on their host cell for many of the high-energy intermediates which includes ATP. This bacterium has a complex life cycle and in order to reproduce needs to infect another cell, therefore, it is generally classified as an obligate intracellular pathogen. At present there are no vaccines which are available against Chlamydophila pneumoniae, this has resulted in a shortage of facilities worldwide which have can identify or diagnose this disease.

INTENDED USE

Human Chlamydia pneumoniae-IgA ELISA kit is designed for analysing in-vitro quantitative amounts of human IgA class antibodies to Chlamydia pneumoniae using plasma and serum samples. This assay has a minimum analytical sensitivity limit to a diagn. 88.9%.

SENSITIVITY

The minimum detection sensitivity level of human Chlamydia pneumoniae IgA using this human Chlamydia pneumoniae-IgA ELISA kit was to a diagn. 88.9%. The dynamic assay range for this kit is to a specific cut-off point.

REFERENCES

  1. Chlamydia pneumoniae IgA seropositivity and sudden sensorineural hearing loss. Otolaryngol Pol. (2004) 58 (3): 427-8. Dünne A.A., et al.
  2. Close association of Chlamydia pneumoniae IgA seropositivity by ELISA with the presence of coronary artery stenosis in haemodialysis patients. Nephrol Dial Transplant. (2005) 20 (9): 1944-50. Nishimura M., et al.
  3. Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest. (2002) 122 (5): 1587-93. Falck G., et al.
  4. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J. (2002) 23 (5): 371-5. Danesh J., et al.
  5. Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgAantibody detection using prolonged incubation and high antigen concentration. APMIS. (2000) 108 (5): 357-62. Gnarpe J., et al.

ADDITIONAL INFORMATION

  • Full Name: Chlamydia Pneumoniae IgA ELISA Kit
  • Reactivity: Human
  • Sample Type: Serum, Plasma
  • Sensitivity: diagn. 88.9%

OTHER RELATED ELISA KITS

TESTIMONIALS arrow icon

Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford